Amiodarone/N-desethylamiodarone population pharmacokinetics in paediatric patients.
arrhythmia
children
modelling and simulation
pharmacokinetics
population analysis
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
20
06
2022
received:
17
11
2021
accepted:
05
07
2022
pubmed:
12
7
2022
medline:
18
11
2022
entrez:
11
7
2022
Statut:
ppublish
Résumé
The population pharmacokinetics of amiodarone and its active metabolite, N-desethylamiodarone (DEA) were investigated in paediatric patients with arrhythmias, mainly supraventricular tachycardias. A total of 55 patients from the Department of Pediatric Intensive Care and Pediatric Cardiology at Necker-Enfants malades Hospital (Paris, France) provided 72 concentrations for both amiodarone and DEA following repeated oral or intravenous administration. Blood samples drawn for biological analyses were used for drug concentrations. Plasma amiodarone concentrations were measured by a liquid chromatography method coupled with mass spectrometry and the data were modelled using the software Monolix 2019R2. Parent pharmacokinetics was described with a 2-compartment open model and the metabolite formation was connected to the central parent compartment. Parameter estimates scaled allometrically on bodyweight (normalized to 70 kg) were, respectively (% relative standard errors, RSEs), 6.32 (31%) and 7.14 L/h (26%) for elimination (CL) and intercompartmental clearances and 167 (31%) and 3930 (32%) L for V
Substances chimiques
desethylamiodarone
M31FU99E3Y
Amiodarone
N3RQ532IUT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5369-5377Informations de copyright
© 2022 British Pharmacological Society.
Références
Losek JD, Endom E, Dietrich A, Stewart G, Zempsky W, Smith K. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med. 1999;33(2):185-191. doi:10.1016/S0196-0644(99)70392-6
Salerno JC, Seslar SP. Supraventricular tachycardia. Arch Pediatr Adolesc Med. 2009;163(3):268-274. doi:10.1001/archpediatrics.2008.547
Perry JC, Garson A. Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: early disappearance and late recurrence. J Am Coll Cardiol. 1990;16(5):1215-1220. doi:10.1016/0735-1097(90)90555-4
Dallefeld SH, Atz AM, Yogev R, et al. A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. J Pharmacokinet Pharmacodyn. 2018;45(3):419-430. doi:10.1007/s10928-018-9576-y
Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000;28(11):1303-1310.
Araki R, Yukawa E, Nakashima MN, et al. Population pharmacokinetic investigation for optimization of amiodarone therapy in Japanese patients. Ther Drug Monit. 2011;33(6):750-756. doi:10.1097/FTD.0b013e318239a728
Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med. 1984;101(4):462-469. doi:10.7326/0003-4819-101-4-462
Haffajee CI, Love JC, Canada AT, Lesko LJ, Asdourian G, Alpert JS. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation. 1983;67(6):1347-1355. doi:10.1161/01.CIR.67.6.1347
Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 2000;67(6):642-652. doi:10.1067/mcp.2000.107047
Coumel P, Fidelle J. Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases. Am Heart J. 1980;100(6):1063-1069. doi:10.1016/0002-8703(80)90214-8
Garson A, Gillette PC, McVey P, et al. Amiodarone treatment of critical arrhythmias in children and young adults. J Am Coll Cardiol. 1984;4(4):749-755. doi:10.1016/S0735-1097(84)80402-7
Bucknall CA, Keeton BR, Curry PV, Tynan MJ, Sutherland GR, Holt DW. Intravenous and oral amiodarone for arrhythmias in children. Br Heart J. 1986;56(3):278-284. doi:10.1136/hrt.56.3.278
Ramusovic S, Läer S, Meibohm B, Lagler FB, Paul T. Pharmacokinetics of intravenous amiodarone in children. Arch Dis Child. 2013;98(12):989-993. doi:10.1136/archdischild-2013-304483
Zhou X-J, Sheiner LB, D’Aquila RT, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999;43(1):121-128. doi:10.1128/AAC.43.1.121
Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154-166. doi:10.1016/j.cmpb.2007.12.002
Sheiner LB, Beal SL. Bayesian Individualization of Pharmacokinetics: Simple Implementation and Comparison with Non-Bayesian Methods. J Pharm Sci. 1982;71(12):1344-1348. doi:10.1002/jps.2600711209
Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48(1):303-332. doi:10.1146/annurev.pharmtox.48.113006.094708
Vadiei K, Troy S, Korth-Bradley J, Chiang ST, Zimmerman JJ. Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J Clin Pharmacol. 1997;37(7):610-617. doi:10.1002/j.1552-4604.1997.tb04343.x
Foissac F, Bouazza N, Valade E, et al. Prediction of drug clearance in children. J Clin Pharmacol. 2015;55(7):739-747. doi:10.1002/jcph.488
Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation. 2005;112(22):3470-3477. doi:10.1161/CIRCULATIONAHA.105.534149